BioSenic S.A.

Information on the total number of voting rights and shares

PRESS RELEASE – REGULATED INFORMATION

Mont-Saint-Guibert, Belgium, 29 February 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on regulated market.

Total amount of share capital on 30 September 2023	EUR 35,100,669
Total number of shares with voting rights on 31 January 2024	163,181,474
Total number of new shares issued between 30 September 2023 and 29 February 2024	20,344,248

Total amount of share capital on 29 February 2024	EUR 35,850,669
Total number of shares with voting rights on 29 February 2024	183,525,722
Total number of voting rights (denominator) on 29 February 2024	183,525,722
Total number of attributed warrants	1,161,556
Total number of convertible bonds outstanding	932
Total number of remaining convertible bonds commitments	60
Total number of shares with voting rights that can be issued following the exercise of the attributed warrants, remaining convertible bonds commitments and the conversion of the convertible bonds	223,892,650(1)

⁽¹⁾

• 1,161,556 shares could be issued in case all 1,161,556 attributed warrants were exercised.
• 285,714 shares could be issued in case all 800 convertible bonds outstanding, issued in the private placement on 6 May 2020, were converted into shares based on the predetermined conversion price of EUR 7.00
• 66,477,854 shares could be issued in case all 60 convertible bonds commitments remaining and all 69 convertible bonds outstanding of the two ABO convertible bonds programs were exercised and converted into shares based on the conversion price of EUR 0.0381330 (95% of the Volume-Weighted-Averaged-Price of BioSenic's shares on 26 February 2024).